The estimated Net Worth of David M Mott is at least 75.5 百万$ dollars as of 12 June 2024. Mr. Mott owns over 6,670 units of Epizyme Inc stock worth over 74,191$ and over the last 13 years he sold EPZM stock worth over 75,141,399$. In addition, he makes 248,912$ as Independent Chairman of the Board at Epizyme Inc.
David has made over 66 trades of the Epizyme Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 6,670 units of EPZM stock worth 9,805$ on 12 June 2024.
The largest trade he's ever made was buying 15,000,000 units of Epizyme Inc stock on 7 September 2018 worth over 25,050,000$. On average, David trades about 607,363 units every 27 days since 2011. As of 12 June 2024 he still owns at least 50,470 units of Epizyme Inc stock.
You can see the complete history of Mr. Mott stock trades at the bottom of the page.
David M. Mott serves as Independent Chairman of the Board of the Company. Mr. Mott has served as a general partner of New Enterprise Associates, Inc., an investment firm focused on venture capital and growth equity investments and a holder of more than 5% of our voting securities, from September 2008 to February 2020, where he led the healthcare investing practice. From 1992 until 2008, Mr. Mott worked at MedImmune, Inc., or MedImmune, a biotechnology company and subsidiary of AstraZeneca Plc, or AstraZeneca, and served in numerous roles during his tenure, including most recently as Chief Executive Officer from October 2000 to July 2008. During that time, Mr. Mott also served as Executive Vice President of AstraZeneca from June 2007 to July 2008 following AstraZeneca’s acquisition of MedImmune in June 2007. Mr. Mott also serves as the Chairman of the board of directors of Ardelyx, Inc. and Adaptimmune and serves on the boards of several private biopharmaceutical companies. Mr. Mott received a B.A. from Dartmouth College.
As the Independent Chairman of the Board of Epizyme Inc, the total compensation of David Mott at Epizyme Inc is 248,912$. There are 10 executives at Epizyme Inc getting paid more, with Robert Bazemore having the highest compensation of 4,173,620$.
David Mott is 54, he's been the Independent Chairman of the Board of Epizyme Inc since 2016. There are 8 older and 7 younger executives at Epizyme Inc. The oldest executive at Epizyme Inc is Kenneth Bate, 69, who is the Independent Director.
David's mailing address filed with the SEC is C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, X0, OX14 4RX.
Over the last 11 years, insiders at Epizyme Inc have traded over 122,255,844$ worth of Epizyme Inc stock and bought 45,285,781 units worth 322,885,823$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Peter J Barris. On average, Epizyme Inc executives and independent directors trade stock every 17 days with the average trade being worth of 394,367$. The most recent stock trade was executed by Grant C. Bogle on 9 August 2022, trading 1,217,500 units of EPZM stock currently worth 1,704,500$.
Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. The Company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them..
Epizyme Inc executives and other stock owners filed with the SEC include: